Background {#Sec1}
==========

Expansion of β-lactamases in Gram-negative rods has been documented as most severe threat to the management of infectious diseases \[[@CR1]--[@CR4]\]. The ever-increasing use of antibiotics with the evolution of intrinsic and acquired resistance has led to the development of resistance mechanism in Gram-negative rods contributing to the expansion of several multi-drug resistance epidemics in hospital environment \[[@CR1], [@CR3], [@CR5]\]. OXA-10 type was known to have narrow spectrum β-lactamase activity; although variant of this enzyme family has expanded-spectrum activity \[[@CR3], [@CR6], [@CR7]\]. It has been extensively associated with infection of Gram-negative bacteria in the last two decades restricting therapeutic options. These genes are often reported to be located within integron gene cassettes \[[@CR3], [@CR4]\]. However, these rare types of beta lactamases are often unreported in the light of current incidence of New Delhi metallo beta lactamase and CTX-M types. The current study reports the dissemination of highly stable *bla* ~OXA-10~ family among diverse group of nosocomial isolates of Gram-negative bacilli within a tertiary referral hospital of the northern part of India.

Methods {#Sec2}
=======

Sample size {#Sec3}
-----------

A total number of 590 consecutive, non duplicate, Gram-negative rods consisting members of *Enterobacteriaceae* family (*Escherichia coli*, *n* = 208; *Klebsiella* spp., *n* = 99; *Proteus* spp., *n* = 28) and non fermenting Gram-negative rods (*Pseudomonas aeruginosa*, *n* = 241; *Acinetobacter baumannii*, *n* = 14) were collected from different clinical specimens spanning a period of 1 year (November 2011--October 2012) from Silchar Medical College and Hospital, India (Table [1](#Tab1){ref-type="table"}).Table 1Clinical and molecular evidence of isolates harboring *bla* ~OXA-10~ β-lactamase familySample numberMale/femaleWards/OPDTypes of clinical specimenIsolatesOther β-lactamase genes/genotypesGenetic environmentPlasmid replicon typeStrain typingWild typesTransformants1.MaleSurgeryPus*P. aeruginosa*OXA-14Type 4FIC, Y--REP type 12.FemaleGynecologyUrine*E. coli*CMY-2--FrepB, YYERIC type 13.MaleMedicineStool*P. aeruginosa*OXA-16Type 1Y--REP type 24.MaleSurgeryUrine*E. coli*OXA-14Type 3YYERIC type 25.FemaleMedicineUrine*E. coli*OXA-14, SHV, CTX-M,Type 4YYERIC type 36.FemaleMedicineUrine*E. coli*OXA-16, SHV, CTX-M, TEM, CMY-2Type 2YYERIC type 47.MaleSurgeryPus*P. aeruginosa*OXA-14, OXA-2, SHVType 5FIB, Y--REP type 38.FemalePediatricsUrine*P. aeruginosa*OXA-16, SHV, CTX-MType 5FIC, Y--REP type 49.FemaleSurgeryPus*E. coli*OXA-16, OXA-14, CTX-MType 3YYERIC type 510.MaleMedicineUrine*E. coli*OXA-14, CTX-MType 1YYERIC type 611.FemaleMedicineUrine*P. aeruginosa*OXA-16, SHV, CTX-M, TEMType 4FIB, Y--REP type 512.FemalePediatricsUrine*P. aeruginosa*OXA-16, CTX-M, TEMType 4FrepB, I1, Y--REP type 613.FemaleSurgeryPus*E. coli*OXA-16, SHV, CTX-M, CMY-2Type 5YYERIC type 714.MalePediatricsOral swab*Proteus* spp.OXA-14Type 3YYERIC type 1315.MaleSurgeryPus*P. aeruginosa*OXA-14, CTX-MType 1FIC, Y--REP type 716.FemaleSurgeryPus*E. coli*OXA-14, SHVType 5YYERIC type 817.MaleSurgeryPus*P. aeruginosa*OXA-16Type 3FIB, Y--REP type 818.MaleSurgeryPus*Klebsiella* spp.OXA-14, SHV, CTX-M, CMY-2Type 4YYERIC type 1019.FemaleGynecologyUrine*P. aeruginosa*OXA-16Type 1Y, K--REP type 920.MalePediatricsUrine*P. aeruginosa*OXA-14, SHV, CTX-MType 3FIC, Y--REP type 1021.FemaleGynecologyUrine*E. coli*OXA-14, SHV, CTX-M,Type 4YYERIC type 922.FemaleMedicineUrine*Klebsiella* spp.OXA-14, SHVType 3YYERIC type 1123.MaleMedicineUrine*P. aeruginosa*OXA-14Type 4FIB, Y--REP type 1124.MaleMedicineUrine*Klebsiella* spp.OXA-14, SHV, CTX-M, TEMType 1YYERIC type 12*OPD* outpatient department

Screening and molecular characterization of β-lactamases {#Sec4}
--------------------------------------------------------

Isolates resistant to at least one of the expanded-spectrum cephalosporins (cefotaxime, ceftazidime, or ceftriaxone) were selected for the study. For amplification and characterization of β-lactamase genes, multiplex PCR was performed (T100, BioRad-USA) with set of five primers namely: *bla* ~CTX-M~ \[[@CR8]\], *bla* ~TEM~, *bla* ~OXA-10~, *bla* ~OXA-2~ \[[@CR9]\] and *bla* ~SHV~ \[[@CR10]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Previously confirmed beta-lactamase genes were used as positive control which were obtained from Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. PCR was performed by using Go-Taq Green Master Mix (Promega, Madison, USA) and products were visualized in 0.5% Agarose gel. PCR product was purified using Gene JET PCR product purification kit (Thermo Scientific, Lithuania) and sequencing was done using Sanger's Method in Xcelris Lab Pvt Ltd in Ahmedabad, India.

PCR assay was also carried out for detection of AmpC genes in donor strains and transformants as described earlier \[[@CR11]\]. Carbapenemase production in donor strains and transformants was tested by modified Hodge test, Imipenem-EDTA disc test \[[@CR12]\] and boronic acid inhibition test \[[@CR13]\] followed by PCR assay targeting *bla* ~OXA-48~ \[[@CR14]\] and *bla* ~OXA-23,\ -24/40\ and\ -58~ \[[@CR15]\].

Study of genetic context and southern blot hybridization {#Sec5}
--------------------------------------------------------

Presence of integron was detected by integrase gene PCR \[[@CR16]\]. To study the variable regions of integron gene cassettes carrying *bla* ~OXA-10~, two PCR assays were performed consequently: in one reaction 5′-CS and reverse primer of *bla* ~OXA-10~ and in other reaction 3′-CS and forward primer of *bla* ~OXA-10~ were used \[[@CR9], [@CR16]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S2). Purified PCR products were cloned on pGEM-T vector (Promega, Madison, USA) and further sequenced. To validate our study, Southern hybridization was performed on agarose gel by in-gel hybridization with the *bla* ~OXA-10~ family specific probe labeled with Dig High Prime Labeling Mix (Roche, Germany) detection Kit. Plasmid DNA was separated on agarose gel and transferred to nylon membrane (Hybond N, Amersham, UK) and hybridized.

Transferability, PCR-based replicon typing and stability of *bla*~OXA-10~ family {#Sec6}
--------------------------------------------------------------------------------

Transformation was carried out using *E. coli* JM107 as recipient. Conjugation experiment was performed taking clinical isolates as donors and a streptomycin resistant *E. coli*-strain B (Genei, Bangalore) as recipient and transconjugants were selected on Luria--Bertani Agar plates containing cefotaxime (0.5 µg/ml) and streptomycin (800 µg/ml). Plasmid transfer was confirmed by colony PCR of transconjugants and transformants with the targeted primers \[[@CR8], [@CR9]\]. Plasmid stability of all *bla* ~OXA-10~ producers as well as their transformants was analyzed by serial passages method for consecutive 115 days without antibiotic pressure \[[@CR17]\]. Colony PCR assay was carried out in the isolates after each passage. Incompatibility typing was carried out by PCR-based replicon typing targeting 18 different replicon types \[[@CR18]\] among all the wild types and their transformants carrying *bla* ~OXA-10.~

Antimicrobial susceptibility and minimum inhibitory concentration determination {#Sec7}
-------------------------------------------------------------------------------

Antimicrobial susceptibility of *bla* ~OXA-10~-harboring donor strains as well as transformants was determined by Kirby--Bauer disc diffusion method towards all non-β-lactam antibiotics (Hi-Media, Mumbai, India) \[[@CR19]\]. MICs of donor as well as transformants and transconjugants were also done against beta lactam groups on Muller Hinton agar (Hi-Media, Mumbai, India) plates by agar dilution method and results were interpreted as per CLSI recommendation \[[@CR19]\].

Strain typing {#Sec8}
-------------

Typing of all *bla* ~OXA-10~ harboring isolates was done by Enterobacterial repetitive intergenic consensus (ERIC) and repetitive extragenic palindromic (REP) PCR \[[@CR20]\].

Results and discussion {#Sec9}
======================

A total of 58.5% (*n* = 345) isolates were resistant to expanded-spectrum cephalosporins. Among them 24 showed amplification with *bla* ~OXA-10~ primers and were further confirmed by sequencing as OXA-14 (n = 15), and OXA-16 (n = 9) derivatives (Table [1](#Tab1){ref-type="table"}). Sequencing results confirmed the presence of resistance determinant within class I integron with five different types of genetic environment (Fig. [1](#Fig1){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). Upstream region of *bla* ~OXA-10~ was occupied by *dfrA12* (Type 1)*, dfrA17* (Type 5)*, dfrA1* (Type 3 and Type 2)*, dfrA7* (Type 4)*, arr2* (Type 2), *aac A4* (Type 2)*, aad A5* (Type 4 and Type 5), while in downstream regions *aad A2* (Type 1), *aad A1* (Type 2 and Type 3), *aac (6′)1b* (Type 4), and *qacE* (Types 1--5) genes were present (Fig. [1](#Fig1){ref-type="fig"}). Plasmid encoding *bla* ~OXA-10~ was successfully transferred in *E. coli* for *Enterobacteriaceae*, while in case of *P. aeruginosa* the attempt was not successful. Hybridization experiment revealed that *bla* ~OXA-10~ carriage was plasmid mediated for *Enterobacteriaceae*. Replicon typing result established that *bla* ~OXA-10~ was encoded within IncY type plasmid (Table [1](#Tab1){ref-type="table"}) (Additional file [2](#MOESM2){ref-type="media"}: Figure S1). All isolates belonging Enterobacteriaceae family were found susceptible to tigecycline while Polymyxin B susceptibility was observed in *P. aeruginosa*. In case of *Enterobacteriaceae,* MICs of donor strain and transformants were observed above the breakpoint against cephalosporins, carbapenems, and monobactams (Table [2](#Tab2){ref-type="table"}) and similar MIC pattern was too observed in *P. aeruginosa* (Table [3](#Tab3){ref-type="table"}). The *bla* ~OXA-10~ was highly stable and none of the isolates lost the gene till 115 serial passages. Modified Hodge test could detect carbapenemase activity in seven isolates and *bla* ~CMY-2~ was also co-carried along with *bla* ~OXA-10~ in four isolates (Table [1](#Tab1){ref-type="table"}). DNA fingerprinting by ERIC (in *E. coli*---ERIC Types 1--9; *Klebsiella* spp.---ERIC Types 1--3; *Proteus* spp.---ERIC Type 1) (Table [1](#Tab1){ref-type="table"}; Additional file [2](#MOESM2){ref-type="media"}: Figure S2) and REP PCR (In *P. aeruginosa*- REP Types 1--11) (Table [1](#Tab1){ref-type="table"}; Additional file [2](#MOESM2){ref-type="media"}: Figure S3) was suggestive that diverse clonal types were present.Fig. 1Schematic representation of variable region of class 1 integron types in OXA-10 producing Gram negative rods Table 2MICs range of *bla* ~OXA-10~ harboring isolates in members of *Enterobacteriaceae*, and their transformantsSample numberAntibiotics (µg/ml)IPMMEMETPATMCAZCTXCROFEPDSTFDSTFDSTFDSTFDSTFDSTFDSTFDSTF2422222646464646464646412812844444441281286464646412812812812854444442562561281286464128128128128644444425625612812812812812812812812892222225125121281281281281281281281281022222\<251251212812812812825625625625613444444256256128128128128128128256256142222225125122562562562562562562562561622222\<2256256256256128128256256256256184444445125121281281281281281281281282144444425625625625625625625625625625622444422256256256256128128256256256256242222\<2\<2256256128128128128256256256256*DS* parent strain, *TF* transformants, *IPM* imipenem, *MEM* meropenem, *ETP* ertapenem, *ATM* aztreonam, *CAZ* ceftazidime, *CTX* cefotaxime, *CRO* ceftriaxone, *FEP* cefepime Table 3MICs range of *bla* ~OXA-10~ harboring *P. aeruginosa*Sample numberAntibiotics (µg/ml)IPMMEMETPATMCAZCTXCROFEP142251212812812812834442562561281282567442256256256256256842\<2256256128128128114445122562562562561222\<225625625625625615\<2\<2\<2256128128128128174445122562562562561922\<225612812812812820442128646464642344425612864128256*E. coli* JM 107 without plasmid\<0.125\<0.125\<0.1250.1250.125\<0.1250.125\<0.125As transformation was not successful in *P. aeruginosa* MIC value of wild types are mentioned above*IPM* imipenem, *MEM* meropenem, *ETP* ertapenem, *ATM* aztreonam, *CAZ* ceftazidime, *CTX* cefotaxime, *CRO* ceftriaxone, *FEP* cefepime

So far, in India predominant types of beta-lactamases are CTX-M-15 and in recent years carbapenem therapy is compromised due to emergence of New Delhi Metallo beta-lactamase from this subcontinent. However, OXA type beta lactamases with extended spectrum activities are rarely reported \[[@CR21], [@CR22]\]. Our data showed that the majority of the isolates were recovered from surgery ward (37.5%; *n* = 9) followed by medicine (33.33%; *n* = 8), pediatrics (16.66%; *n* = 4), and gynecology (12.5%; *n* = 3). Carriage of *bla* ~OXA-10~ within integron with diverse genetic environment comprising different coexisting-resistant determinant shows its multiple sources of acquisition and complicacy while determining the therapeutic options. It was also found that *bla* ~OXA-10~ was horizontally transferable in *Enterobacteriaceae* family which was supported by transformation and conjugation. However, unsuccessful transfer of *bla* ~OXA-10~ in *P. aeruginosa* could be due to their plasmid not being replicated within *E. coli* recipient or a chromosomal location of the gene. High MIC against carbapenems could be due to presence of some gene types which was not amplified by our target primers. Capability of the organisms to retain the resistant gene even after withdrawal of antibiotic pressure underscores their vertical transfer and persistence in the cell, which possibly can be the reason of expansion of this resistance determinant within hospital environment as well as in community. High MICs of the donor strain as well as their transformants could be due to the coexistence of another β-lactamase enzyme as observed in the current study.

Conclusion {#Sec10}
==========

To the best of our knowledge this is the first report of gene cassette-mediated carriage of *bla* ~OXA-10~ from India. Their acquisition and dissemination as well as adaptation against high antibiotic pressure in the hospital environment demands immediate measure to prevent transmission of these genetic vehicles, by the adoption of proper infection control measures and treatment policies.
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================

 {#Sec11}

**Additional file 1: Table S1.** Oligonucleotides used as primers for amplification of different ESBL genes. **Table S2.** Primers used for characterization of integron. **Additional file 2: Figure S1.** PCR detection of IncY (765 bp) in transformants plasmid harbouring *bla* ~OXA-10.~ Lane 1: Negative control; Lane 2-8: 765 bp IncY. **Figure S2.** DNA finger printing of *Enterobacteriace* by ERIC PCR. Lane L: 10 Kb DNA hyper ladder I; Lane 1--9: ERIC pattern of *E. coli* Types 1--9; Lane 10--12: ERIC pattern of *Klebsiella* spp. Types 1--3. Lane 13: ERIC pattern of *Proteus* spp. ERIC Type-1. **Figure S3.** DNA finger printing of *P. aeruginosa* by REP PCR, *P. aeruginosa* Rep Types 1--11.
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